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Introduction: High circulating serum vascular endothelial growth
factor (VEGF) levels might reflect enhanced angiogenesis in pa-
tients suffering from non-small cell lung cancer (NSCLC). This
study aimed at determining the prognostic significance of circulating
VEGF as a prognostic factor in NSCLC.
Methods: Four hundred fifty-one histologically or cytologically
proven and previously untreated NSCLC patients have been studied.
Median follow-up was 13 years and 9 months. Eleven clinical and
biologic variables were recorded. The levels of circulating VEGF
were measured in the serum by quantitative immunoassay. Patients
have had received conventional treatment (without anti-VEGF ther-
apy) according to the international guidelines. All statistical tests
were two-sided.
Results: Receiver operating characteristic curves (area under the
ROC curve: 0.66 0.05) showed that circulating VEGF serum level
did not demonstrate a high sensitivity–specificity relationship, and
therefore, demonstrated a low ability to differentiate NSCLC from
benign lung diseases. A 600 pg/mL level of circulating VEGF serum
was considered as threshold with 40.8% of NSCLC patients pre-
senting with a high level. The circulating VEGF distribution differed
significantly according to disease stage, nodal status, and perfor-
mance status (PS), with the highest levels observed in metastatic
stage, positive mediastinal nodal status, and poor PS. In univariate
survival analysis, patients with a high pretreatment circulating
VEGF serum level proved to have a shorter overall survival when
compared with patients presenting with a circulating VEGF serum
level600 pg/mL. However, in the Cox proportional hazard model,
this variable was not included in the panel of independent determi-
nants of a poor outcome that was as follows: advanced or metastatic
diseases according to the 6th edition of the staging system, PS 2,
nodal status N2–3, metastatic disease, neuron-specific enolase12.5
ng/mL, CYFRA 21-1 3.6 ng/mL.
Conclusion: The prognostic information given by a high circulating
VEGF serum level is not an independent determinant of survival
owing to a high relationship with main prognostic variables such as
PS, stage of the disease, and nodal status. This finding does not
preclude a putative prognostic impact of in situ detection of VEGF
and VEGF receptors in tumor specimen.
Key Words: Circulating vascular endothelial growth factor, Angio-
genesis, Non-small cell lung cancer, Prognosis.
(J Thorac Oncol. 2008;3: 1119–1126)
Treatment decisions for non-small cell lung cancer(NSCLC) in routine practice mainly depended on aware-
ness of main prognostic determinants.1–4 For patients accrued
in clinical trials, knowledge of prognostic determinants is
also critical to stratify randomization according to pertinent
factors and to adjust statistical survival impact of treatment.5
In the Eastern Cooperative Oncology Group trial 1594 ran-
domized trial of chemotherapy in metastatic NSCLC, patients
presenting with performance status (PS) greater than 1 expe-
rienced an excessively high rate of toxicity,6 and female
patients proved to have a better prognosis than male patients.5
Hitherto, the most widely accepted negative prognostic de-
terminants of NSCLC are metastatic disease stage, positive
nodal status, poor PS,1,2 weight loss3 and, although incon-
stancy, male gender.5 Nonsquamous histologies have been
variously reported as positive prognostic factors but whether
or not this feature is independent of or correlated with patient
gender (adenocarcinoma having been more frequently ob-
served in women) is still debatable.7 We previously published
that the prognostic information given by a high serum
CYFRA 21-1 level is independent from other well-known
variables such as PS and disease stage, and is perennial
throughout extended follow-up period. A high neuron-spe-
cific enolase (NSE) level also prognosticates a poor outcome
probably by reflecting tumor heterogeneity and underesti-
mated neuroendocrine differentiation.
NSCLC clinically behaves aggressively with a rapid
growth and metastatic spread. As both features are thought to
be angiogenic-dependent processes, therapy targeting angio-
genesis has been considered as a potential new approach.
Bevacizumab is a recombinant humanized monoclonal anti-
body that binds vascular endothelial growth factor (VEGF).
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When given in combination with standard platinum-based
doublet regimens, bevacizumab has been shown to prolong
survival of previously untreated advanced NSCLC when
compared with chemotherapy alone.8,9 The recent approval of
bevacizumab in combination with first-line therapy for a
selected subgroup of NSCLC stimulated further clinical re-
searches of other angiogenesis targeted therapies. In this
setting, different proteins involved in the angiogenesis could
be detected in the serum of patients suffering from various
malignancies, including lung cancer.10 Therefore, circulating
VEGF serum level might be regarded as one of putative
markers, and could help the appraisal of angiogenesis.
Hitherto, the prognostication of patient outcome using
angiogenesis serum marker remains a matter of controversy.
To accurately determine whether or not circulating VEGF
serum level adds prognostic information, the herein study
simultaneous appraised pretreatment level of circulating
VEGF serum and other known putative survival determinants
in a large NSCLC population followed-up during a long
period of time.
PATIENTS AND METHODS
Patients
Four hundred fifty-one consecutive patients referred to
the Montpellier—Nîmes University Hospital between Febru-
ary 1990 and June 1998 were prospectively entered in a
databank informing a sera bank (Table 1). Eligibility criteria
consisted of histologically or cytologically proven and pre-
viously untreated NSCLC. Consequently, patients suffering
from small cell lung cancer and patients admitted for adjuvant
treatment (after surgery), second-line therapy or palliative
care after anticancer treatment failure were not eligible.
Histologic subclassification was done according to the WHO
classification.11 PS was estimated according to the Eastern
Cooperative Oncology Group12 and the percentage of weight
loss during the previous 4 months was recorded. Staging was
performed by exhaustive procedures according to the 6th
edition of the Union Internationale Contre le Cancer tumor
node metastases classification.13 The following investigations
were performed: clinical examination, standard chest radio-
graph, computed tomography (CT) scan of chest and upper
abdomen, fiber-optic bronchoscopy, liver sonography, and
bone scanning. Mediastinoscopy was used to establish nodal
status in NSCLC patients with nonmetastatic disease and
evidence of mediastinal lymph node enlargement on chest
CT-scan. Brain CT scan was done on clinical indication until
1992 and systematically performed thereafter.
Controls
The serum markers were measured in 49 consecutive
patients with nonmalignant pulmonary diseases. Patients in
this benign chronic lung disease group were affected by
diseases resulting from chronic obstructive pulmonary dis-
ease with or without infectious complications, postinfectious
bronchiectiasis, silicosis, and severe asthma. Most of the
patients in this group suffered from tobacco consumption.
Treatment
A medical panel composed of thoracic surgeons, chest
physicians, radiologists, radiotherapists, and medical oncolo-
gists discussed the case of each patient to design a treatment
program to be submitted for patient’s approval. Particular
attention was paid to the agreement between each individual
proposal and the international guidelines.
NSCLC patients with stage I or II disease underwent
surgery in an attempt at complete resection. Patients suffering
from pathologically demonstrated N2 disease received cis-
platin-based neoadjuvant chemotherapy followed by surgery
whenever possible. Other patients with PS 2 and distant
metastases (stage IV) or gross mediastinal involvement (stage
IIIb and unresectable stage IIIa) were treated by a cisplatin-
based chemotherapy. Radiotherapy was applied in locally
TABLE 1. Patients’ Demography and Disease
Characteristics
Variables No. of Patients (%)
Total 451
Age (yr), median  SD 61  10
Gender
Male 409 (91)
Female 42 (9)
ECOG performance status
2 237 (52.9)
2 211 (47.1)
Stage grouping (mountain)
I 41 (9)
II 4 (0.9)
IIIa 56 (12.4)
IIIb 146 (32.3)
IV 204 (45.2)
Histology
Squamous cell 250 (55.4)
Adenocarcinoma 132 (29.3)
Large cell carcinoma 69 (15.3)
Weight loss (%)
5% 307 (71.2)
5% 124 (28.8)
Blood leukocyte count
10,000/L 242 (54.4)
10,000/L 203 (45.6)
Serum NSE level
12.5 ng/mL 335 (74.6)
12.5 ng/mL 114 (25.4)
Serum CYFRA 21-1 level
3.6 ng/mL 227 (50.3)
3.6 ng/mL 224 (49.6)
Serum VEGF level
600 pg/mL 267 (59.2)
600 pg/mL 184 (40.8)
Serum albumin level
32 g/L 66 (15.1)
32 g/L 370 (84.9)
ECOG, Eastern Cooperative Oncology Group; NSE, neuron-specific enolase;
VEGF, vascular endothelial growth factor.
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advanced stages according to a concurrent chemoradiother-
apy schedule.14 As adjuvant to anticancer therapy, best sup-
portive care, including palliative radiation therapy when
needed, was proposed to patients according to their symp-
toms and impact of disease on quality of life. Treatment was
decided upon according to clinical and routine biologic find-
ings and without knowledge of the circulating VEGF,
CYFRA 21-1 or NSE levels. Disease stage, PS, and comor-
bidities were obviously taken into account in therapeutic
choice. Hence, treatment was not considered as a prognostic
variable in this study.
Biochemical Measurements
A blood sample was taken from each patient at
presentation, the serum was separated and stored at
180°C until tested.
Serum NSE was measured by ELSA NSE™, a solid
phase two-site immunoradiometric assay (Cis Biointerna-
tional, Gif/Yvette, France). Two monoclonal antibodies were
prepared against sterically remote antigenic sites on the NSE
molecule, the first one specific for the NSE is coated in the
ELSA solid phase, and the second radiolabeled with
125iodine is used as a tracer. The NSE molecules present in
the standards or the samples to be tested were sandwiched
between the two antibodies. After the formation of the coated
antibody/antigen/iodinated antibody sandwich, the unbound
tracer was easily removed by a washing step. The radioac-
tivity bound to the ELSA is proportional to the concentration
of NSE present in the sample. The calculated concentration of
NSE was expressed in ng/mL.
CYFRA 21-1TM (Centocor Diagnostics, Malvern, PA
and Cis Biointernational) is a solid phase immunoradiometric
assay based on the two-site sandwich method. In this method
the cytokeratin 19 is recognized by two mouse MoAb, KS
19-1 and BM 19-21, directed against two different epitopes of
a fragment of cytokeratin subunit 19, which is referred to as
serum CYFRA 21-1. MoAb KS 19-1 coated polystyrene
spheres were incubated with 200 L of patient serum, control
serum, or standard curve (composed of the following con-
centrations of cytokeratin 19: 0, 3, 8, 25, and 50 ng/mL) for
20 hours between 2 and 8°C. Afterward, the solid phase was
washed with distilled water and then incubated with 0.85
CI/mL of 125iodine labeled BM 19-21 for 3 hours between
2 and 8°C. Finally, the solid phase was washed again with
distilled water to cancel the nonfixed labeled reagents. Ra-
dioactivity was counted in a well-type gamma counter (Au-
togamma; Packard Instrument Company, Chicago, IL) and
expressed in cpm. The calculated concentration of cytokera-
tin 19 was expressed in ng/mL.
The upper limit of normal values for leukocytes was
10,000/L. The lower limits of normal values were 32 g/L
and 135 mmol/L for albumin and serum sodium, respectively.
Serum VEGF level was measured using the Calbio-
chem Human enzyme-linked immunosorbent assay kit
(QIA51, Merck Biosciences, Darmstadt, Germany). This
sandwich immunoassay uses a monoclonal antibody immo-
bilized onto the surface of the plastic wells to capture VEGF
present in sera and a polyclonal antibody tracer, labeled using
horseradish peroxidase. The kit measured both the isoforms,
VEGF165 and VEGF121, and allows its use to quantify natural
human VEGF protein in sera. The sample to be assayed (100
L of patients’ samples and standards) are pipetted into the
wells and any human VEGF present binds to the capture
antibody. After incubation at room temperature for 2 hours,
wells were washed 3 times and incubated with 200 L of the
VEGF conjugate for 2 hours. Each well was washed as
before, and then incubated for 25 minutes with 50 L of
substrate solution (H2O2  tetramethylbenzidine). The reac-
tion was stopped with 50 L of H2SO4 2N and absorbance
was measured using a spectrophotometer plate reader at dual
wavelengths of 450/540 nm. The standard curve was com-
posed of the following concentrations of Sf21-expressed
recombinant human VEGF 165: 31.2, 62.5, 125, 250, 500,
and 1000 pg/mL, and concentrations of unknowns were
determined by interpolation from the standard curve. The
sensitivity of the test is 9.0 pg/mL. The levels of circulating
VEGF were measured blindly without any clinical informa-
tion given.
Statistics
Receiver operating characteristic (ROC) curves were
constructed using both patient and control subject serum
marker levels in an attempt to establish a sensitivity–speci-
ficity relationship. Areas under the ROC curves were calcu-
lated.15 A comparison between the areas under the ROC
curves (AUC-ROC) was made using the Z statistic (two-
tailed test). Version 1.0 of AccuROC for Windows 95 soft-
ware was used.16
The serum tumor marker was not distributed normally;
thus, to analyze the distribution of tumor markers in subsets
of patients, results were expressed as median, and variation
was expressed as interquartile range (IR). Nonparametric
statistical analyses were used: differences between two inde-
pendent groups were determined by means of the Mann-
Whitney U test with the Bonferroni correction for multiple
comparisons; differences between more than two groups were
determined by means of Kruskal–Wallis one-way analysis of
variance.
Survival was defined from the date of sampling to the
date of death of any cause. Survival data were updated in
February 2008 and 12 patients (2.6%) were lost to follow-up.
Median follow-up was 13 years and 9 months. Probability of
survival was estimated by the Kaplan–Meier method.17 Sin-
gle variable survival analyses were done by means of Wil-
coxon and log-rank tests and multivariate regression was
done with Cox’s model.18 Cox’s model analysis was written
after a Boolean coding of all variables which reach a 0.15 p
level using the results of univariate analysis. For each vari-
able, the proportional hazard assumption was tested graphi-
cally: survival was analyzed using the SAS software package.
RESULTS
Marker Distribution According to Pretreatment
Variables
ROC curve for circulating VEGF serum was con-
structed with specificity calculated using the results of titra-
tion in the nonmalignant lung disease group, whereas sensi-
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tivity was measured in the whole NSCLC population (Figure
1). Areas under the ROC curves (AUC-ROC) were 0.66 
0.05; Z statistics: 3.0; p  0.002 when compared with the
no-discrimination line. These results suggested that circulat-
ing VEGF serum level did not demonstrate a clear sensitivity–
specificity relationship when its ability to differentiate
NSCLC from benign lung diseases was tested. By using this
ROC curve, a 600 pg/mL level of circulating VEGF serum
was considered as threshold with 40.8% of NSCLC patients
presenting with a high level. In the whole NSCLC population,
median (IR) was 518 pg/mL (309 to 870); and circulating
VEGF serum levels ranged from 6 to 2456 pg/mL.
The circulating VEGF serum level varied significantly
according to stage grouping in NSCLC inasmuch as the
highest level was observed in stage IV disease and the lowest
in stage I–II (Kruskal–Wallis test: 11.2; p  0.01; Figure 2).
Similarly, patients presenting with a mediastinal lymph node
involvement (Kruskal–Wallis test: 11.1; p  0.01; Figure 3)
or a poor PS (Kruskal–Wallis test: 26.6; p  0.0001; Figure
4) have higher median and IR circulating VEGF serum when
compared with patients presenting with opposite features.
Survival Analysis
Survival was analyzed in the whole patient population.
Patients lost to follow-up were considered for the real time of
participation to the study and right censored afterward. Uni-
variate analyses were shown in Table 2. Patients with a high
pretreatment circulating VEGF serum level proved to have a
shorter overall survival when compared with patients present-
ing with a circulating VEGF serum level 600 pg/mL (me-
dian survival in months 95% CI: 6.4 5.3–8.7 and 10.6
8.3–13.2 respectively, log-rank: p  0.0002; Figure 5).
However, in the Cox proportional hazard model, this variable
was not included in panel of independent determinants of a
poor outcome that were as follows: Mountain stage grouping
(advanced or metastatic diseases according to the 6th edition
of the staging system), PS 2 or 3, nodal status N2–3, metastatic
disease, serum NSE 12.5 ng/mL, and serum CYFRA 21-1
3.6 ng/mL (Table 3).
DISCUSSION
In this study, we investigated whether or not pretreat-
ment circulating VEGF serum level, as one of the angiogen-
esis markers, is a prognostic factor of NSCLC patient sur-
FIGURE 1. Receiver operating characteristic constructed
using the sensitivity–specificity relationship circulating vascu-
lar endothelial growth factor (VEGF) serum to discriminate
non-small cell lung cancer (NSCLC) patients and patients
with a nonmalignant pulmonary disease. AUC, area under
the curve; SE, standard error.
FIGURE 2. Circulating vascular endothelial growth factor
(VEGF) serum distribution according to Mountain stage
grouping in non-small cell lung cancer (6th edition of the
staging system). Horizontal bar, median value; columns, in-
terquartile range; vertical bar, 95% confidence interval.
Kruskal–Wallis test: 11.2; p  0.01.
FIGURE 3. Circulating vascular endothelial growth factor
(VEGF) serum distribution according to the nodal status in
non-small cell lung cancer. Horizontal bar, median value;
columns, interquartile range; vertical bar, 95% confidence
interval. Kruskal–Wallis test: 11.1; p  0.01.
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vival. Although patients presenting with a high circulating
VEGF serum level proved to have a shorter survival than
patients with circulating VEGF lower than its threshold
value, this feature does not independently determine survival
in multivariate analysis. Possible interpretation of this nega-
tive result could be based on high relationship between
circulating VEGF serum and main prognostic variables such
as PS, stage of the disease and nodal status.
Angiogenesis is recognized as an important feature of
tumor progression in many human malignancies,19 including
NSCLC. Although antiangiogenic agents aim at limiting
stromal expansion rather than modifying tumor cell prolifer-
ation, they are considered as indirect ways in achieving tumor
expansion arrest. Interestingly, the antitumor effect of anti-
angiogenic therapy is considered not to be affected by tumor
resistance such as multidrug resistance that limits conven-
tional anticancer therapies.
Different clues suggesting the importance of angiogen-
esis in promoting tumor growth have been observed in
NSCLC. Some are in situ markers of angiogenesis and other
are circulating serum markers.
In the former group, a high microvessel density has
been shown to indicate a poor prognosis.20 This feature
obviously seems as the final result of angiogenesis. There-
fore, it is not surprising that most of the literature on this
subject concluded in the same way regarding a poorer prog-
nostic outcome for patients presenting with a high count of
microvessel density.20,21 Further explorations of in situ mark-
ers have also suggested that high immunohistochemical stain-
ing using either anti-VEGF antibodies or antiplatelet-derived
endothelial cell growth factor correlates with high microves-
sel density and poor patient outcome.21 Although more de-
batable, the negative prognostic significance of high staining
for matrix metalloproteinases (MMP) have been suggested,
particularly, MMP-922 and MMP-2.23,24 MMP-2 expression,
as analyzed by protein-staining status or by in situ hybridiza-
tion, proved to correlate with overall survival, but reached
FIGURE 4. Circulating vascular endothelial growth factor
(VEGF) serum distribution according to performance status
in non-small cell lung cancer. Horizontal bar, median value;
columns, interquartile range; vertical bar, 95% confidence
interval. Kruskal–Wallis test: 26.6; p  0.0001.
TABLE 2. Univariate Analysis in NSCLC Patients
Variable and
Levels
Median Survival
(95% CI, mo)
p
Wilcoxon Log-Rank
Sex
Female 13.8 (8.1–18.2) 0.42 0.41
Male 8.2 (6.9–9.7)
Agea
70 yr 7.2 (5.4–10.7) 0.29 0.38
70 yr 8.9 (7.3–10.6)
Performance status
0–1 14.5 (11.8–17.3) 104 104
1 5.2 (4.2–6)
Tumor status
T1–2 14.5 (9.6–20.8) 3 	 10
4 104
T3–4 7.6 (6.5–9.1)
Nodal status
N0–1 18.4 (13.6–24.8) 10
4 104
N2–3 6.9 (6.1–8.3)
Metastases
M0 13.6 (10.7–15.8) 104 104
M1 5.4 (4.7–6.2)
Stage groupinga
I–II 81 (32.4–NR) 104 104
IIIa 15.8 (8.9–27.6)
IIIb–IV 6.7 (5.8–8.3)
Histology
SQC 8.9 (6.9–10.8) 0.95 0.88
Non-SQC 8.2 (6.5–10.6)
Weight lost
5% 9.6 (7.8–10.9) 0.012 0.125
5% 6.5 (4.7–9.1)
Circulating VEGF
serum
600 pg/mL 10.6 (8.3–13.2) 104 0.0002
600 pg/mL 6.4 (5.3–8.7)
Serum albumin
32 g/L 9.7 (7.8–11) 104 104
32 g/L 3.8 (2–5.4)
Leukocytes
10,000/mL 12.4 (10.6–14.5) 104 104
10,000/mL 5.4 (4.3–6.6)
Neuron specific enolase
12.5 ng/mL 10 (8.3–11.8) 104 104
12.5 ng/mL 5.3 (3.7–7.6)
CYFRA 21-1
3.6 ng/mL 14.5 (10.8–16.3) 104 104
3.6 ng/mL 5.9 (5–6.9)
a Sixth edition of the staging system.
SQC, squamous cell carcinoma; NR, not reached; 95% CI, 95% confidence interval;
VEGF, vascular endothelial growth factor; NSCLC, non-small cell lung cancer.
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significance in the univariate analysis only, whereas it was
not a prognostic determinant of lung cancer in multivariate
analysis.24 Conversely, low expression of tissue inhibitors of
matrix metalloproteinase resulting in a tissue inhibitors of
matrix metalloproteinase–MMP imbalance has been consid-
ered as a putative target for antiangiogenic therapy.22 De-
struction of the extracellular matrix is a necessary prerequi-
site for vessel invasion toward metastasic process. Although
MMPs play a key role in the initial step of angiogenesis,
MMP inhibitors failed to demonstrate a survival benefit in
cancer. This observation might have resulted from a partial or
incomplete angiogenesis process blockade. Finally, adhesion
molecules, such as integrin v3 which is over expressed in
lung cancer, are considered as important step in tumor growth
and angiogenesis and have been recently explored as targets
in NSCLC therapy.25
Circulating angiogenic factor are detectable in the se-
rum of patients suffering from different human malignancies.
The most evaluated markers are VEGF, basic fibroblast
growth factor, platelet-derived growth factor; transforming
growth factor, interleukin-8; hepatocyte growth factor, plate-
let-derived endothelial cell growth factor, and angiogenin.19,26
In some malignancies such as gastrointestinal cancer27 or
melanoma,28 high serum levels of VEGF, interleukin-8, and
basic fibroblast growth factor have been identified as prog-
nostic factors. In a population of 125 patients affected by
various stage of melanoma and who underwent different
combinations of cytokines and cytotoxic therapies, both over-
all and progression free survivals were independently deter-
mined by the three aforementioned circulating angiogenic
factors.28
In lung cancer, recent literature regarding circulating
angiogenic agents produced conflicting results.10,29–33 It has
been suggested that circulating VEGF serum level could be
regarded as a surrogate for evaluating tumor-related angio-
genesis. Some studies have pointed out a possible correlation
between a high serum VEGF level and a poor prognosis in
NSCLC patients.31,33 Although the prognosis significance of
circulating VEGF serum level has been supported by a strong
rationale and several concordant studies, other studies, in-
cluding the herein reported, did not. One can consider that the
positive studies have had evaluated serum level in small
patient populations with sometimes undefined time of serum
sampling. In a study stating that circulating VEGF serum is a
prognostic determinant of NSCLC, a careful analysis of the
results indicates that this parameter shared its prognostic
information with other well-known prognostic factors such as
disease stage and PS.31 In multivariate analysis, only the
latter well-known prognostic factors were independent prog-
nostic determinants, whereas circulating VEGF serum level
was not retained into the Cox model, a similar observation to
the one done in our study.
Strengths of our study are (i) a levelheaded number of
accrued patients allowing a good reliability of survival anal-
yses of 11 clinical and biologic variables in multivariate
analysis; (ii) a long-term follow-up and low rate of patients
lost to follow-up. These features authorize confidence in the
survival analyses.
There are also some limitations. Although patients have
been prospectively accrued in this study, the original purpose
of this sera bank (strictly stored at 180°C until tested) was
to evaluate the prognostic meaning of a high serum CYFRA
21-1 level. This immunoradiometric assay referred to as the
detection of a perfectly identified cytokeratin 19 fragment
(epitope sequences lying within the sequences 311–335 and
346–367).34 The prognostic significance of CYFRA 21-1 has
been demonstrated by our research program,35 and thereafter,
confirmed in a meta-analysis.4 In a previously published
study, we demonstrated that the prognostic information given
by a high serum CYFRA 21-1 level is independent from other
well-known variables such as PS and disease stage, and is
perennial throughout extended follow-up period. A high NSE
level also prognosticates a poor outcome probably by reflect-
ing tumor heterogeneity and underestimated neuroendocrine
differentiation.36 However, in the nineties, the case for throm-
bocytopenia, as a putative prognostic variable, was not sus-
pected and the databank was not developed for angiogenic
factor analysis purpose. It is now recognized that both platelet
count and circulating VEGF serum might be correlated.30
Because we are not able to give data regarding the former
parameter there is part of uncertainty regarding the survival
significance of a high circulation VEFG level. Another lim-
FIGURE 5. Probability of survival of non-small cell lung
cancer patients with normal and elevated pretreatment cir-
culating vascular endothelial growth factor (VEGF) serum
level; Kaplan–Meier curves were constructed taking into ac-
count the whole population survival. Dotted line, circulating
VEGF serum 600 pg/mL; dark line, circulating VEGF serum
600 pg/mL. Median survival in months 95% CI: 6.4 5.3–
8.7 and 10.6 8.3–13.2, respectively, log-rank: p  0.0002.
TABLE 3. Estimated Hazard Ratio for Significant Variables
Variables Hazard Ratio (95% CI) p
Mountain stage IIIa–IV 2.23 (1.33–3.73) 0.0023
NSE 12.5 ng/mL 1.61 (1.27–2.05) 0.0001
CYFRA 21-1 3.6 ng/mL 1.50 (1.20–1.86) 0.0003
Nodal status N2–3 1.64 (1.24–2.17) 0.0005
Metastatic disease 1.58 (1.25–2.00) 0.0001
Performance status 2–4 1.77 (1.43–2.19) 0.0001
CI, confidence interval; NSE, neuron-specific enolase.
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itation in the herein study was the long period accrual time
and the early start of the study (1990). Nevertheless, the use
of cisplatin-based chemotherapy for patients suffering from
locally advanced or metastatic disease was early recognized
in our institution insofar as we actively participated in the
study by Le Chevalier, the first one demonstrating the benefit
of third-generation drug plus cisplatin chemotherapy when
compared with second-generation drug combination or sin-
gle-drug chemotherapies.37 A similar commitment in research
and application of concurrent chemoradiotherapy has lead to
the combined modality treatment of unresectable stage III
NSCLC patients in our study. Therefore, one can consider
that our patient population received first-line treatment in a
manner that has anticipated the main current guidelines re-
garding (i) use of cisplatin plus third-generation drug dou-
blets in metastatic patients and (ii) multimodality treatments
favoring concurrent chemoradiotherapy in stage IIIb.
Interpretation of negative result from our study is
shared in common with other studies analyzing circulating
angiogenic factors in lung cancer patients. (i) We investigated
one angiogenic agent (VEGF) and tried to correlate its level
with prognosis, but none of the patient received antiangio-
genic therapy. However, in the randomized study evaluating
combination of chemotherapy and bevacizumab,8 VEGF lev-
els were predictive of response to antiangiogenic therapy but
not survival.38 Serum VEGF could vary in patients receiving
bevacizumab in other malignancies suggesting that circulat-
ing VEGF might be useful in predicting and monitoring
tumor response to anticancer therapies.26 Therefore, the con-
clusion of our study does not preclude a possible role of
circulating VEGF serum as a surrogate marker for angiogen-
esis in patient who undergo antiangiogenesis therapy. (ii) It is
tempting to define serum markers of angiogenesis, and sim-
ilar attempts are made for other signaling pathways that
promote NSCLC progression such as epidermal growth factor
receptor activation. However, complex pathways are rarely
reflected by a simple circulating marker. In this setting, we
previously demonstrated that neither HER-2 nor EGFR ex-
tracellular domains specific levels were associated with a
particular prognosis of NSCLC patients.39 A similar phenom-
enon might have occurred in the case of circulating VEGF
serum that seems a weaker prognostic indicator than its in situ
counterpart or its in situ receptors detections.40–43 (iii) Fi-
nally, taking into account the high number of endogenous
factors promoting endothelial cells differentiation and prolif-
eration toward tumor angiogenesis, considering a sole factor
as a putative surrogate for such a complex process might
sound as a naive concept.19,44
In the herein study a high circulating VEGF serum did
not independently determine prognosis of NSCLC: patients
with such a high circulating angiogenic marker proved to
have a poorer overall survival than patients with the opposite
feature owing to the fact that serum VEGF is strongly
correlated with disease stage. This finding could be consid-
ered as an additional clue that angiogenesis process partly
induces tumor progression and, consequently, contributes to a
negative impact on NSCLC prognosis. However, nodal sta-
tus, stage of the disease and PS that are clearly correlated
with a high circulating VEGF serum remain the most impor-
tant prognostic variables suggesting that circulating VEGF
level is only one of the numerous endogenous factors that
promote angiogenesis.
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